secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001723128-23-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reports preliminary Q1 2023 revenue $550-560M (+12% YoY); affirms FY guidance
--------------------------------------------------------------------------------

- Net revenue $550-560M, up ~12% YoY; loss before taxes $10M-$0 (improvement ~50%).
- Adjusted EBITDA $115-120M, up ~18% YoY.
- Long-term debt $2.692B; net debt reduced to $2.541B from $2.647B at Dec 31.
- Management cites strong generics, biosimilars uptake, Rytary/Unithroid growth; IPX203 PDUFA June 30.
- Full year 2023 financial guidance affirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/0001723128-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/amrx-20230417.htm
  HTML page:      https://secwatch.observer/filing/0001723128-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer